Internal Medicine, Infectious Disease · Wilmington, DE
NPI
1043624463
Since 2014
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
501 W 14th St Fl 6
Wilmington, DE, 19801
Phone (302) 320-1300
Groups this clinician bills Medicare through
Medicare paid, 2024
$6,158
111 services
Medicare patients, 2024
65
Average age 64
Drug cost, 2024
$5.2M
2,412 prescriptions
Company payments, 2025
$125
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert A Jakubowski was code 99214 (office e&m - established), 89 times for 60 patients. In total Robert A Jakubowski billed 111 services in 5 codes, and Medicare paid $6,158.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-12-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 89 | 60 | $56.89 | $5,064 |
By year: 2023 $6,023 for 94 services; 2024 $6,158 for 111 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert A Jakubowski prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 692 prescriptions and refills. In total Robert A Jakubowski wrote 2,412 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 692 | 704 | 100 | $2.8M |
| Rosuvastatin Calcium Generic | 131 | 235 | 33 | $931 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 110 | 112 | 15 | $533K |
| Atorvastatin Calcium Generic | 104 | 168 | 26 | $466 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 101 | 101 | 16 | $388K |
| Dovato Dolutegravir Sodium/Lamivudine | 94 | 94 | 16 | $274K |
| Darunavir Generic | 82 | 82 | Under 11 | $97K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 78 | 78 | Under 11 | $304K |
| Tivicay Dolutegravir Sodium | 64 | 66 | 11 | $152K |
| Amlodipine Besylate Generic | 58 | 96 | 13 | $180 |
| Ritonavir Generic | 57 | 65 | Under 11 | $5,939 |
| Varenicline Tartrate Generic | 38 | 39 | Under 11 | $8,840 |
| Descovy Emtricitabine/Tenofov Alafenam | 38 | 38 | Under 11 | $80K |
| Prezcobix Darunavir/Cobicistat | 36 | 36 | Under 11 | $90K |
| Juluca Dolutegravir/Rilpivirine | 30 | 30 | Under 11 | $104K |
Brand drugs: 1,366 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert A Jakubowski $125 ($125 in general payments such as food, travel and fees) from 1 company. The largest payer was Gilead Sciences, Inc. with $125.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 1 | $125 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.